Guideline decision tool · Cardiology
❤️

Acute Coronary Syndrome: Reperfusion & Antithrombotics — free guideline decision tool

This tool gives the reperfusion or intervention timing and the antiplatelet/anticoagulation strategy for acute coronary syndrome, separating STEMI from NSTE-ACS.

Open guideline tool →
Computed locally — no data uploaded. For licensed clinicians.
📋

Guideline-based

Implements the decision logic from published clinical guidelines.

🖥️

Runs in your browser

No installation. Enter the patient's values and get a guideline recommendation instantly.

🔒

Data stays local

Nothing is uploaded. Results are for licensed clinicians only.

Worked calculation

The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.

ACS typeSTEMI (ST-elevation)
Primary PCI feasible within 120 min (for STEMI)Yes
Time from onset (for STEMI)12–24 h
NSTE-ACS risk stratificationHigh risk

→StrategySTEMI: reperfuse as early as possible

  • Reperfusion:Primary PCI (preferred; FMC-to-wire-crossing ≤ where possible)
  • Antiplatelet:Aspirin loading + P2Y12 (ticagrelor preferred, or clopidogrel), DAPT (duration per current guideline)
  • Anticoagulation:Parenteral anticoagulation: unfractionated heparin or bivalirudin for primary PCI (bivalirudin favored with high bleeding risk); enoxaparin/UFH for thrombolysis
ACS typeNSTE-ACS (NSTEMI/unstable angina)
Primary PCI feasible within 120 min (for STEMI)No
Time from onset (for STEMI)> 24 h
NSTE-ACS risk stratificationLow risk

→StrategyNSTE-ACS: risk stratification defines intervention

  • Intervention timing:No thrombolysis; by risk stratification: Selective intervention or non-invasive evaluation first
  • Antiplatelet:Aspirin loading + P2Y12 (ticagrelor preferred; prasugrel limited to known coronary anatomy planned for PCI), DAPT (duration per current guideline)
  • Anticoagulation:Parenteral anticoagulation: fondaparinux preferred for conservative treatment; UFH or enoxaparin for planned intervention

Common questions

What is Acute Coronary Syndrome: Reperfusion & Antithrombotics?

This tool gives the reperfusion or intervention timing and the antiplatelet/anticoagulation strategy for acute coronary syndrome, separating STEMI from NSTE-ACS.

How is Acute Coronary Syndrome: Reperfusion & Antithrombotics calculated? What is the core formula?

STEMI: primary PCI if feasible ≤ 120 min, else thrombolysis within 12 h then transfer. NSTE-ACS: no thrombolysis, intervention by risk (very-high, high, intermediate, low selective). DAPT (aspirin + ticagrelor) + parenteral anticoagulant.

When is Acute Coronary Syndrome: Reperfusion & Antithrombotics used?

Use to choose reperfusion in STEMI (primary PCI vs thrombolysis by time and feasibility) and intervention timing in NSTE-ACS by risk, with the antithrombotic backbone.

What are the key clinical points for Acute Coronary Syndrome: Reperfusion & Antithrombotics?

NSTE-ACS is never thrombolysed; the decision is intervention timing by risk, whereas STEMI hinges on the earliest reperfusion. (original synthesis · not guideline verbatim) Ticagrelor is the preferred P2Y12 agent; prasugrel is limited to known coronary anatomy planned for PCI. Add β-blocker, statin, and ACEi/ARB unless contraindicated, and assess bleeding risk (CRUSADE).

What are the limits and cautions when using Acute Coronary Syndrome: Reperfusion & Antithrombotics?

For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.

Does Acute Coronary Syndrome: Reperfusion & Antithrombotics upload patient data? Where is it calculated?

Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.

How is Acute Coronary Syndrome: Reperfusion & Antithrombotics calculated in practice? Can you show a worked example?

Inputs: ACS type STEMI (ST-elevation), Primary PCI feasible within 120 min (for STEMI) Yes, Time from onset (for STEMI) 12–24 h, NSTE-ACS risk stratification High risk → Result: Strategy STEMI: reperfuse as early as possible(Reperfusion: Primary PCI (preferred; FMC-to-wire-crossing ≤ where possible), Antiplatelet: Aspirin loading + P2Y12 (ticagrelor preferred, or clopidogrel), DAPT (duration per current guideline), Anticoagulation: Parenteral anticoagulation: unfractionated heparin or bivalirudin for primary PCI (bivalirudin favored with high bleeding risk); enoxaparin/UFH for thrombolysis) Inputs: ACS type NSTE-ACS (NSTEMI/unstable angina), Primary PCI feasible within 120 min (for STEMI) No, Time from onset (for STEMI) > 24 h, NSTE-ACS risk stratification Low risk → Result: Strategy NSTE-ACS: risk stratification defines intervention(Intervention timing: No thrombolysis; by risk stratification: Selective intervention or non-invasive evaluation first, Antiplatelet: Aspirin loading + P2Y12 (ticagrelor preferred; prasugrel limited to known coronary anatomy planned for PCI), DAPT (duration per current guideline), Anticoagulation: Parenteral anticoagulation: fondaparinux preferred for conservative treatment; UFH or enoxaparin for planned intervention)

❤️

Run Acute Coronary Syndrome: Reperfusion & Antithrombotics now

This tool gives the reperfusion or intervention timing and the antiplatelet/anticoagulation strategy for acute coronary syndrome, separating STEMI from NSTE-ACS.

Open guideline tool →

For licensed clinicians. Not a substitute for clinical judgement.

Share on XLinkedInWhatsAppEmail

Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.

Related guideline tools

For use by licensed clinicians and clinical researchers. Computed locally in your browser — no data is uploaded. Not a substitute for clinical judgement.

Water does not race to be first — it strives only to flow on, unbroken

Yuan Doctor
Tertiary-hospital clinical team · local compute · no upload
© 2026 Yuan Doctor · www.yuandoctor.com · Developed & reviewed by a tertiary-hospital clinical team